International Clinical Psychopharmacology最新文献_第10页

Capillary blood sampling for the determination of clozapine concentrations: analytical validation and patient experience. 毛细管血液取样测定氯氮平浓度:分析验证和患者经验。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-01-01 Epub Date: 2023-08-07 DOI: 10.1097/YIC.0000000000000494

Bianca D Breken, Koen P Grootens, Annemieke M Vermeulen Windsant-van den Tweel, Walter A Hermens, Hieronymus J Derijks

{"title":"Capillary blood sampling for the determination of clozapine concentrations: analytical validation and patient experience.","authors":"Bianca D Breken, Koen P Grootens, Annemieke M Vermeulen Windsant-van den Tweel, Walter A Hermens, Hieronymus J Derijks","doi":"10.1097/YIC.0000000000000494","DOIUrl":"10.1097/YIC.0000000000000494","url":null,"abstract":"Patients may be reluctant to start clozapine (CLZ) because of the frequent blood sampling needed for white blood cell monitoring, but also therapeutic drug monitoring of CLZ. Finger prick, instead of venepuncture, might lower the threshold to CLZ use. The aim of this study was to determine whether CLZ concentrations are the same in capillary and venous blood samples. Capillary blood was drawn by finger prick and collected in the Hem-Col tube. Paired capillary and venous blood samples were collected from inpatients and outpatients of a mental health institute. Patients were asked to rate pain, experience, and preference for blood sampling method. Passing-Bablok analysis of 40 paired samples showed that CLZ concentrations were statistically equal in capillary and venous samples {slope 0.96 [95% confidence interval (CI): 0.88-1.04], intercept -6.86 (95% CI: -30.75 to 24.13)}. Venepuncture was the preferred method based on the experience ( P = 0.009) and preference ( P = 0.043) items. In conclusion, CLZ concentrations were similar in venous and capillary blood samples. Venepuncture appeared to be preferred to finger prick for blood sampling. Our results emphasize the importance of consulting patients' individual preference for blood sampling method.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"23-28"},"PeriodicalIF":2.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10326456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Differentiating the third generation of antipsychotics: a focus on lumateperone's similarities and differences. 区分第三代抗精神病药物：关注鲁马替培隆的异同。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-01-01 Epub Date: 2023-09-20 DOI: 10.1097/YIC.0000000000000510

Gloria M Munayco Maldonado, Thomas L Schwartz

{"title":"Differentiating the third generation of antipsychotics: a focus on lumateperone's similarities and differences.","authors":"Gloria M Munayco Maldonado, Thomas L Schwartz","doi":"10.1097/YIC.0000000000000510","DOIUrl":"10.1097/YIC.0000000000000510","url":null,"abstract":"The development of atypical antipsychotics has evolved to include newer pharmacodynamic properties. Lumateperone, aripiprazole, brexpiprazole, and cariprazine are all dopamine-2 receptor partial agonists with varying receptor affinities. This review aims to compare the clinical and pharmacodynamic differences among these four atypical antipsychotics, all of which are unique when compared to first- and second-generation antipsychotics. For consideration is further delineating these agents as being third-generation antipsychotics. PubMed searches were conducted to compile preclinical and clinical studies derived from animal models and human subjects. Information gathered included pharmacological mechanisms, clinical efficacy, future-oriented clinical approaches, and adverse effects. Efficacy for the shared indications of these drugs seems comparable. Differences among these drugs lie more in their adverse effect profiles. For example, lumateperone was found to have the lowest rate of weight gain while brexpiprazole was found to have the highest rate of weight gain associated with increased appetite. Aripiprazole had the lowest rates of extrapyramidal symptoms not including akathisia while cariprazine had the highest. All four agents reviewed have a variety of receptor affinities, which likely generates a variety of different adverse effects. This suggests that in any given patient, clinicians may see differential clinical effects.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"4-16"},"PeriodicalIF":2.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41118992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Diabetes mellitus in patients with chronic bipolar disorder: prevalence, clinical correlates and relationship with homocysteine. 慢性双相情感障碍患者的糖尿病:患病率、临床相关性及与同型半胱氨酸的关系

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2023-11-20 DOI: 10.1097/YIC.0000000000000504

Li Mu, Dachun Chen, Meihong Xiu, Huixia Zhou, Dongmei Wang, Xiang-Yang Zhang

{"title":"Diabetes mellitus in patients with chronic bipolar disorder: prevalence, clinical correlates and relationship with homocysteine.","authors":"Li Mu, Dachun Chen, Meihong Xiu, Huixia Zhou, Dongmei Wang, Xiang-Yang Zhang","doi":"10.1097/YIC.0000000000000504","DOIUrl":"10.1097/YIC.0000000000000504","url":null,"abstract":"Comorbid diabetes mellitus in patients with bipolar disorder may contribute to increased morbidity and mortality. To determine the prevalence of diabetes mellitus in bipolar disorder patients and its clinico-demographic and homocysteine correlates, we conducted a cross-sectional survey of 195 bipolar disorder inpatients. They received questionnaires, clinical measurements and laboratory tests to assess demographic characteristics, anthropometric variables, clinical variables and plasma homocysteine levels. The prevalence of diabetes mellitus (including type 1, type 2 and special types) in Chinese bipolar disorder patients was 14.9%. Analysis of variance or chi-square test showed that compared with non-diabetic bipolar disorder patients, diabetic bipolar disorder patients were older, more often married, had a longer duration of disease, took less olanzapine and had a higher frequency of hypertension. However, there were no significant differences in body mass index (BMI) and homocysteine levels between diabetic and non-diabetic bipolar disorder patients. Logistic regression analysis showed that marital status and duration of disease were independently associated with diabetes mellitus in patients with bipolar disorder after controlling for age, use of olanzapine, presence of hypertension, BMI and homocysteine levels. These findings shed light on the clinico-demographic correlates of the increased prevalence of diabetes mellitus in bipolar disorder patients, rather than the correlation with some metabolic risk factors.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2023-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138046805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neuroscience-based nomenclature as a teaching tool, introduction and pilot study. 基于神经科学的命名法作为一种教学工具，介绍和试点研究。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2023-09-01 Epub Date: 2023-04-12 DOI: 10.1097/YIC.0000000000000470

Sasson Zemach, Daniel Minkin Levy, Joseph Zohar

{"title":"Neuroscience-based nomenclature as a teaching tool, introduction and pilot study.","authors":"Sasson Zemach, Daniel Minkin Levy, Joseph Zohar","doi":"10.1097/YIC.0000000000000470","DOIUrl":"10.1097/YIC.0000000000000470","url":null,"abstract":"Neuroscience-based nomenclature (NbN) is a pharmacologically-driven nomenclature aiming to replace the current disease-based nomenclature of psychotropics, focusing on pharmacology and mode-of-action to encourage scientifically-minded prescribing. NbN might also be used as a teaching tool as it presents the depth and richness of the neuroscience of psychotropics. This study examines the effect of using NbN in student curriculum. Fifty-six medical students during clerkship in psychiatry, divided into a control group ( n = 20), taught standard psychopharmacology, and an intervention group ( n = 36) introduced with NbN. Both groups filled out identical questionnaires at the beginning and end of the clerkship, including questions of knowledge on psychopharmacology, views on current terminology and interest in psychiatric residency. Comparing the average change in scorings (delta post-pre) for each item in intervention vs. control questionnaires, the intervention group showed a significantly larger positive delta in 6 out of 10 items than the control group. Mean scores did not differ significantly between the two groups in the pre-questionnaires, while significantly higher scores were shown for the intervention group in within- and between-group comparisons. Introduction of NbN was associated with a better educational experience, a deeper understanding of psychotropics and increased interest in psychiatric residency.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":"38 5","pages":"329-335"},"PeriodicalIF":2.1,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11191058/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10334898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ketamine for depression: a potential role in requests for Medical Aid in Dying? 氯胺酮治疗抑郁症：在申请临终医疗救助中的潜在作用？

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2023-09-01 Epub Date: 2023-04-18 DOI: 10.1097/YIC.0000000000000462

Nicolas Garel, Michka Nazon, Kamran Naghi, Elena Willis, Karl Looper, Soham Rej, Kyle T Greenway

{"title":"Ketamine for depression: a potential role in requests for Medical Aid in Dying?","authors":"Nicolas Garel, Michka Nazon, Kamran Naghi, Elena Willis, Karl Looper, Soham Rej, Kyle T Greenway","doi":"10.1097/YIC.0000000000000462","DOIUrl":"10.1097/YIC.0000000000000462","url":null,"abstract":"Medical Aid in Dying (MAiD) is the act of a healthcare provider ending a patient's life, at their request, due to unbearable suffering from a grievous and incurable disease. Access to MAiD has expanded in the last decade and, more recently, it has been made available for psychiatric illnesses in a few countries. Recent studies have found that such psychiatric requests are rapidly increasing and primarily involve mood disorders as the primary condition. Nevertheless, MAiD for psychiatric disorders is associated with significant controversy and debate, especially regarding the definition and determination of irremediability - that a given patient lacks any reasonable prospect for recovery. In this article, we report the case of a Canadian patient who was actively requesting Medical Assistance in Dying for severe and prolonged treatment-resistant depression until she experienced remarkable benefits from a course of intravenous ketamine infusions. To our knowledge, this is the first report of ketamine or any other intervention yielding remission in a patient who would have otherwise likely been eligible for MAiD for depression. We discuss implications for the evaluation of similar requests and, more specifically, why a trial of ketamine warrants consideration.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":"38 5","pages":"352-355"},"PeriodicalIF":2.6,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10334899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical specificity profile for novel rapid acting antidepressant drugs. 新型速效抗抑郁药物的临床特异性概况。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2023-09-01 Epub Date: 2023-06-30 DOI: 10.1097/YIC.0000000000000488

Mauro Scala, Giuseppe Fanelli, Diana De Ronchi, Alessandro Serretti, Chiara Fabbri

{"title":"Clinical specificity profile for novel rapid acting antidepressant drugs.","authors":"Mauro Scala, Giuseppe Fanelli, Diana De Ronchi, Alessandro Serretti, Chiara Fabbri","doi":"10.1097/YIC.0000000000000488","DOIUrl":"10.1097/YIC.0000000000000488","url":null,"abstract":"Mood disorders are recurrent/chronic diseases with variable clinical remission rates. Available antidepressants are not effective in all patients and often show a relevant response latency, with a range of adverse events, including weight gain and sexual dysfunction. Novel rapid agents were developed with the aim of overcoming at least in part these issues. Novel drugs target glutamate, gamma-aminobutyric acid, orexin, and other receptors, providing a broader range of pharmacodynamic mechanisms, that is, expected to increase the possibility of personalizing treatments on the individual clinical profile. These new drugs were developed with the aim of combining a rapid action, a tolerable profile, and higher effectiveness on specific symptoms, which were relatively poorly targeted by standard antidepressants, such as anhedonia and response to reward, suicidal ideation/behaviours, insomnia, cognitive deficits, and irritability. This review discusses the clinical specificity profile of new antidepressants, namely 4-chlorokynurenine (AV-101), dextromethorphan-bupropion, pregn-4-en-20-yn-3-one (PH-10), pimavanserin, PRAX-114, psilocybin, esmethadone (REL-1017/dextromethadone), seltorexant (JNJ-42847922/MIN-202), and zuranolone (SAGE-217). The main aim is to provide an overview of the efficacy/tolerability of these compounds in patients with mood disorders having different symptom/comorbidity patterns, to help clinicians in the optimization of the risk/benefit ratio when prescribing these drugs.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":"38 5","pages":"297-328"},"PeriodicalIF":2.6,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373854/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10318395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antidepressant emergent mood switch in major depressive disorder: onset, clinical correlates and impact on suicidality. 重度抑郁障碍中的抗抑郁药突发情绪转换：发病、临床相关性及对自杀的影响。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2023-09-01 Epub Date: 2023-06-09 DOI: 10.1097/YIC.0000000000000479

Paolo Olgiati, Alessandro Serretti

{"title":"Antidepressant emergent mood switch in major depressive disorder: onset, clinical correlates and impact on suicidality.","authors":"Paolo Olgiati, Alessandro Serretti","doi":"10.1097/YIC.0000000000000479","DOIUrl":"10.1097/YIC.0000000000000479","url":null,"abstract":"Antidepressant (AD)- emergent mood switch (AEMS) is a common complication of bipolar depression. This study aimed to investigate the prevalence and clinical correlates of subthreshold AEMS (i.e. not fulfilling DSM criteria for hypomanic episodes) in major depressive disorder (MDD) and, prognostically, its impact on AD treatment outcome and suicidality. The study involved 425 outpatients with MDD followed during the acute phase (12 weeks) and continuation (weeks 13-28) AD treatment. AEMS was assessed through the Altman Self-Rating Mania scale (ASRM ≥ 6). Several clinical features differentiated individuals with or without subthreshold AEMS (n = 204 vs. 221): negative self-perception [odds ratio (OR) 1.017-1.565]; panic disorder (OR 1.000-1.091); subthreshold hypomanic episodes (OR 1.466-13.352); childhood emotional abuse (OR 1.053-2.447); lifetime suicidal behaviour (OR 1.027-1.236); AD-related remission (χ 2 = 22.903 P < 0.0001) and suicide ideation (χ 2 = 16.701 P < 0.0001). In AEMS earlier onset showed a strong correlation with bipolar spectrum disorder (overall score: P = 0.0053; mixed depression: P = 0.0154; subthreshold hypomania: P = 0.0150) whereas late-onset was associated with more severe suicidal behaviour ( P < 0.001). In conclusion, our results demonstrate that subthreshold mood switches occur frequently in unipolar depression during acute AD treatment as well as in continuation phase. Time of switch onset seems to have the greatest diagnostic and prognostic value.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":"38 5","pages":"342-351"},"PeriodicalIF":2.6,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373846/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9963846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Gordian knot of the immune-redox systems' interactions in psychosis. 精神病中免疫-氧化还原系统相互作用的死结。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2023-09-01 Epub Date: 2023-06-12 DOI: 10.1097/YIC.0000000000000481

Evangelos Karanikas

{"title":"The Gordian knot of the immune-redox systems' interactions in psychosis.","authors":"Evangelos Karanikas","doi":"10.1097/YIC.0000000000000481","DOIUrl":"10.1097/YIC.0000000000000481","url":null,"abstract":"During the last decades the attempt to enlighten the pathobiological substrate of psychosis, from merely focusing on neurotransmitters, has expanded into new areas like the immune and redox systems. Indeed, the inflammatory hypothesis concerning psychosis etiopathology has exponentially grown with findings reflecting dysfunction/aberration of the immune/redox systems' effector components namely cytokines, chemokines, CRP, complement system, antibodies, pro-/anti-oxidants, oxidative stress byproducts just to name a few. Yet, we still lie far from comprehending the underlying cellular mechanisms, their causality directions, and the moderating/mediating parameters affecting these systems; let alone the inter-systemic (between immune and redox) interactions. Findings from preclinical studies on the stress field have provided evidence indicative of multifaceted interactions among the immune and redox components so tightly intertwined as a Gordian knot. Interestingly the literature concerning the interactions between these same systems in the context of psychosis appears minimal (if not absent) and ambiguous. This review attempts to draw a frame of the immune-redox systems' interactions starting from basic research on the stress field and expanding on clinical studies with cohorts with psychosis, hoping to instigate new avenues of research.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":"38 5","pages":"285-296"},"PeriodicalIF":2.6,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9963851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cariprazine: an augmentation strategy for treatment-resistant schizophrenia with pro-cognitive and anti-hostility effects. 卡哌嗪：治疗耐药性精神分裂症的增强策略，具有促进认知和抗敌意的作用。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2023-09-01 Epub Date: 2023-06-12 DOI: 10.1097/YIC.0000000000000469

Chelsea Boydstun, Sean Lynch, Patrick DiGenova

引用次数: 0

Innovation in psychopharmacology. 精神药理学的创新。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2023-09-01 Epub Date: 2023-07-10 DOI: 10.1097/YIC.0000000000000493

Alessandro Serretti

引用次数: 0